Search - tctmd.com

Displaying 601 - 620 of 724

Sort: Relevancy | Date

News Conference News EuroPCR 2012

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Caitlin E. Cox

May 22, 2012

News Conference News EuroPCR 2012

CT-Derived FFR Enables Accurate ‘Virtual Stenting’

Jason Kahn

May 16, 2012

News Industry News

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

May 15, 2012

News Daily News SCAI 2012

Robot-Assisted PCI Safe, Reduces Operator Radiation Exposure

Jason Kahn

May 11, 2012

News Industry News

New Data From Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients

May 11, 2012

News Daily News

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

May 10, 2012

News Daily News

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

Caitlin E. Cox

May 09, 2012

News Features

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

Caitlin E. Cox

May 07, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

News Daily News

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Caitlin E. Cox

April 26, 2012

Presentation

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

Presenter: M. Patel

April 25, 2012

News Industry News

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

April 20, 2012

News Daily News

German Reimbursement System May Result in Increase in Interventional Procedures

April 17, 2012

News Daily News

Baseline Anemia Raises Risk for Stent Thrombosis After DES

L.A. McKeown

April 04, 2012

News Daily News

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

April 03, 2012

News Daily News

PRODIGY Published: No Advantage to Long-term Clopidogrel

April 03, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Conference News ACC 2012

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

L.A. McKeown

March 24, 2012

Advertisement

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

CT-Derived FFR Enables Accurate ‘Virtual Stenting’

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

Robot-Assisted PCI Safe, Reduces Operator Radiation Exposure

New Data From Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

German Reimbursement System May Result in Increase in Interventional Procedures

Baseline Anemia Raises Risk for Stent Thrombosis After DES

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

PRODIGY Published: No Advantage to Long-term Clopidogrel

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content